Decipher by Veracyte

Join Veracyte, Inc.'s Decipher team at the Western Section of the AUA in Koloa, Hawaii! Stop by Booth 212 to learn how we're transforming prostate cancer patient care. We'll be here until October 31. See you there! #WSAUA24 #ProstateCancer

Save the date! Veracyte, Inc.'s Decipher team will be at the 103rd Annual Meeting of the South Central Section of the AUA, CO, on October 30-November 2. Stop by our booth to discuss how we're transforming #ProstateCancer patient care.

Heading to Koloa, HI, for the Western Section of the American Urological Association from October 27 to November 1? So are we! Stop by our booth to learn how we're transforming care for #ProstateCancer patients. #WSAUA24

This month's #EmployeeSpotlight goes to Juan Avila. Juan, has consistently demonstrated excellent performance as a Materials Management Specialist. His drive to succeed, and proactively helpful approach to customer service have significantly contributed to the effectiveness of inventory operations. He has shown remarkable dedication to maintaining high standards of accuracy and reliability in managing materials, ensuring that all processes run smoothly and lab personnel material requirements are met. Juan strives to accomplish all assigned tasks to the best of his ability. His positive attitude and strong work ethic are greatly appreciated by the entire team.

Save the date! Veracyte, Inc.'s Decipher team will be at the South Carolina Urological Association Annual Meeting in Greenville, SC, on October 25-26. Stop by our booth to discuss how we're transforming #ProstateCancer patient care.

An analysis of Veracyte, Inc.'s Decipher Prostate in patients with de novo metastatic #ProstateCancer from a large-scale real-world clinical and transcriptomic data linkage was presented at #ASTRO24. Algorithms were developed to identify patients with de novo metastatic disease, and analysis identified that these patients tend to have higher PSA levels, very high Decipher scores, and specific mutations in tumor suppressor genes. This analysis and continued research is expected to enhance the understanding of de novo metastatic disease biology and inform treatment approaches. Click on the link to read more: https://lnkd.in/gaUJ3FuS

At #ESMO24, the results of an ancillary study of STAMPEDE were presented, evaluating the Decipher Score for prediction of survival benefit when combining docetaxel with hormone therapy in metastatic hormone sensitive #ProstateCancer patients. High Decipher Score identified patients were more likely to benefit from treatment intensification with docetaxel, independently of tumor volume. Decipher is the first molecular classifier to show a statistically significant interaction with docetaxel in randomized metastatic prostate cancer patients. Learn more here: https://lnkd.in/g-bxADDF

Join us October 10-12 in San Juan, Puerto Rico, for the 75th Annual Meeting of the Puerto Rico Urological Association! Visit the Veracyte, Inc. #DecipherTeam to explore how we support patients living with #ProstateCancer.

Decipher was analyzed in a recently published phase 2 trial, which showed that in #ProstateCancer patients with high-risk biochemical recurrence, olaparib monotherapy had the greatest benefit in participants with BRCA2 alterations. Interestingly, those with BRCA2 alterations exhibited statistically significant differences in RNA-based expression signatures and had very high Decipher scores. Click on the link to read more: https://lnkd.in/gbepubba

Join us at the Southern Society of Urological Surgeons in Las Vegas, NV, from October 4-7! Stop by our booth to chat with the team about how Veracyte, Inc.’s #DecipherProstate can empower your treatment planning with clarity and confidence. #ProstateCancer